<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Erleada-II-009 EN PI Clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.PIBulletSecondIndent, li.PIBulletSecondIndent, div.PIBulletSecondIndent
	{mso-style-name:"PI Bullet Second Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:1.0in;
	text-indent:-.5in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
p.StyleBodytextAgencyUnderline, li.StyleBodytextAgencyUnderline, div.StyleBodytextAgencyUnderline
	{mso-style-name:"Style Body text \(Agency\) + Underline";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	text-decoration:underline;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.a, li.a, div.a
	{mso-style-name:"";
	mso-style-link:"Texto comentario Car1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TextocomentarioCar1
	{mso-style-name:"Texto comentario Car1";
	mso-style-link:"";
	font-family:"Times New Roman",serif;}
p.CommentTextCharCharChar, li.CommentTextCharCharChar, div.CommentTextCharCharChar
	{mso-style-name:"Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	mso-style-link:"Kommentartext Zchn\,Comment Text Char Char Char Zchn\,Comment Text Char1 Char Zchn\,Comment Text Char1 Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.KommentartextZchn
	{mso-style-name:"Kommentartext Zchn\,Comment Text Char Char Char Zchn\,Comment Text Char1 Char Zchn\,Comment Text Char1 Zchn";
	mso-style-link:"Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	font-family:"Times New Roman",serif;}
p.0, li.0, div.0
	{mso-style-name:_0;
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BodyText12, li.BodyText12, div.BodyText12
	{mso-style-name:"Body Text 12";
	mso-style-link:"Body Text 12 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BodyText12Char
	{mso-style-name:"Body Text 12 Char";
	mso-style-link:"Body Text 12";
	font-family:"Times New Roman",serif;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.EUCP-Heading-1, li.EUCP-Heading-1, div.EUCP-Heading-1
	{mso-style-name:EUCP-Heading-1;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EUCP-Heading-2, li.EUCP-Heading-2, div.EUCP-Heading-2
	{mso-style-name:EUCP-Heading-2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	color:black;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=EUCP-Heading-1><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB><img width=21 height=18
src="Erleada-II-009%20EN%20PI%20Clea_files/image001.gif"></span><span
lang=EN-GB>This medicinal product is subject to additional monitoring. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section&nbsp;4.8
for how to report adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk500502765"><span lang=EN-GB>Erleada</span></a><span
lang=EN-GB> 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
of apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film-coated tablet (tablet).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Slightly yellowish to greyish green, oblong&#8209;shaped,
film&#8209;coated tablets (16.7&nbsp;mm long x 8.7&nbsp;mm wide), debossed with
&#8220;AR 60&#8221; on one side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk499729533"></a><a name="_Hlk529168387"><span
lang=EN-GB>Erleada is indicated:</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in adult men for the treatment of non&#8209;metastatic
castration&#8209;resistant prostate cancer (nmCRPC) who are at high risk of
developing metastatic disease (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in adult men for the treatment of metastatic
hormone-sensitive prostate cancer (mHSPC) in combination with androgen
deprivation therapy (ADT) (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with apalutamide should be initiated
and supervised by specialist physicians experienced in the medical treatment of
prostate cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose is 240&nbsp;mg (four 60&nbsp;mg
tablets) as an oral single daily dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medical castration with gonadotropin
releasing hormone analogue (GnRHa) should be continued during treatment in
patients not surgically castrated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>If a dose is missed, it should be taken as soon as possible
on the same day with a return to the normal schedule the following day. <span
lang=EN-GB>Extra tablets should not be taken to make up the missed dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>If a &#8805;&nbsp;Grade&nbsp;3 toxicity or an intolerable adverse
reaction is experienced by the patient, dosing should be held rather than
permanently discontinuing treatment until symptoms improve to
&#8804;&nbsp;Grade&nbsp;1 or original grade, then should be resumed at the same
dose or a reduced dose (180&nbsp;mg or 120&nbsp;mg), if warranted. For the most
common adverse reactions, see section 4.8.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Special
populations</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is necessary for elderly
patients (see sections&nbsp;5.1 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Renal
impairment</span></u></i></p>

<p class=MsoNormal>No dose adjustment is necessary for patients with mild to
moderate renal impairment. <a name="_Hlk518549870"></a></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Caution is required in patients with severe renal impairment
as apalutamide has not been studied in this patient population (see section&nbsp;5.2).
If treatment is started, patients should be monitored for the adverse reactions
listed in section 4.8 and dose reduce as per section 4.2 Posology and method of
administration. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Hepatic
impairment</span></u></i></p>

<p class=MsoNormal>No dose adjustment is necessary for patients with baseline
mild or moderate hepatic impairment (Child&#8209;Pugh Class A and B, respectively).
</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Erleada is not recommended in patients with severe hepatic impairment
as there are no data in this patient population and apalutamide is primarily
hepatically eliminated (see section&nbsp;5.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There is no
relevant use of apalutamide in the paediatric population.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablets should be swallowed whole and
can be taken with or without food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Women who are or may become pregnant (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Seizure</span></u></p>

<p class=MsoNormal>Erleada is not recommended in patients with a history of
seizures or other predisposing factors including, but not limited to, underlying
brain injury, recent stroke (within one year), primary brain tumours or brain
metastases. If a seizure develops during treatment with Erleada, treatment
should be discontinued permanently. <span lang=EN-GB>T</span>he risk of seizure
may be increased in patients receiving concomitant medicinal products that
lower the seizure threshold. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In two randomised studies (SPARTAN and TITAN), seizure
occurred in 0.6% of patients receiving apalutamide and in 0.2% of patients
treated with placebo. These studies excluded patients with a history of seizure
or predisposing factors for seizure.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>There is no clinical experience in re&#8209;administering Erleada
to patients who experienced a seizure.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Falls and
fractures</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Falls and fractures occurred in patients
receiving apalutamide (see section 4.8). Patients should be evaluated for
fracture and fall risk before starting Erleada and should continue to be monitored
and managed according to established treatment guidelines and use of bone-targeted
agents should be considered.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Ischaemic heart disease
and ischaemic cerebrovascular disorders</u></p>

<p class=MsoNormal>Ischaemic heart disease and ischaemic cerebrovascular
disorders, including events leading to death, occurred in patients treated with
apalutamide (see section 4.8). The majority of patients had cardiac/cerebrovascular
ischaemic disease risk factors. Patients should be monitored for signs and
symptoms of ischaemic heart disease and ischaemic cerebrovascular disorders. Management
of risk factors, such as hypertension, diabetes, or dyslipidaemia should be
optimised as per standard of care.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Concomitant
use with other medicinal products </span></u></p>

<p class=MsoNormal>Apalutamide is a potent enzyme inducer and may lead to loss
of efficacy of many commonly used medicinal products (see section 4.5). A
review of concomitant medicinal products should therefore be conducted when apalutamide
treatment is initiated. Concomitant use of apalutamide with medicinal products
that are sensitive substrates of many metabolising enzymes or transporters (see
section 4.5) should generally be avoided if their therapeutic effect is of
large importance to the patient, and if dose adjustments cannot easily be
performed based on monitoring of efficacy or plasma concentrations. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Co&#8209;administration of apalutamide with warfarin and
coumarin-like anticoagulants should be avoided. If Erleada is co&#8209;administered
with an anticoagulant metabolised by CYP2C9 (such as warfarin or
acenocoumarol), additional International Normalised Ratio (INR) monitoring
should be conducted (see section 4.5).</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Recent cardiovascular
disease</u></p>

<p class=MsoNormal>Patients with clinically significant cardiovascular disease
in the past 6 months including severe/unstable angina, myocardial infarction,
symptomatic congestive heart failure, arterial or venous thromboembolic events
(e.g., pulmonary embolism, cerebrovascular accident including transient ischaemic
attacks), or clinically significant ventricular arrhythmias were excluded from
the clinical studies. Therefore, the safety of apalutamide in these patients
has not been established. If Erleada is prescribed, patients with clinically
significant cardiovascular disease should be monitored for risk factors such as
hypercholesterolaemia, hypertriglyceridaemia, or other cardio-metabolic
disorders (see section 4.8). Patients should be treated, if appropriate, after
initiating Erleada for these conditions according to established treatment
guidelines. </p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Androgen deprivation
therapy may prolong the QT interval</u></p>

<p class=MsoNormal>In patients with a history of or risk factors for QT
prolongation and in patients receiving concomitant medicinal products that might
prolong the QT interval (see section 4.5), physicians should assess the
benefit-risk ratio including the potential for Torsade de pointes prior to
initiating Erleada.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>The elimination of apalutamide and formation of its active
metabolite, N&#8209;desmethyl apalutamide, is mediated by both CYP2C8 and
CYP3A4 to a similar extent at steady-state. No clinically meaningful changes in
their overall exposure is expected as a result of drug interaction with inhibitors
or inducers of CYP2C8 or CYP3A4. Apalutamide is an inducer of enzymes and transporters
and may lead to an increase in elimination of many commonly used medicinal
products.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Potential for other
medicinal products to affect apalutamide exposures</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk525282369"><i>Medicinal
products</i></a><i> that inhibit CYP2C8</i></p>

<p class=MsoNormal>CYP2C8 plays a role in the elimination of apalutamide and in
the formation of its active metabolite. In a drug<a name="_Hlk519146368">&#8209;</a>drug
interaction study, the C<sub>max</sub> of apalutamide decreased by 21% while
AUC increased by 68% following co&#8209;administration of apalutamide 240&nbsp;mg
single dose with gemfibrozil (strong CYP2C8 inhibitor). For the active moieties
(sum of apalutamide plus the potency adjusted active metabolite), C<sub>max</sub>
decreased by 21% while AUC increased by 45%. <span lang=EN-GB>No initial dose
adjustment is necessary when Erleada is co&#8209;administered with a strong
inhibitor of CYP2C8 (e.g., gemfibrozil, clopidogrel) however, a reduction of the
Erleada dose based on tolerability <a name="_Hlk496512254">should be considered
(see section&nbsp;4.2)</a>. Mild or moderate inhibitors of CYP2C8 are not
expected to affect the exposure of apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Medicinal products that
inhibit CYP3A4</i></p>

<p class=MsoNormal>CYP3A4 plays a role in the elimination of apalutamide and in
the formation of its active metabolite. In a drug&#8209;drug interaction study,
the C<sub>max</sub> of apalutamide decreased by 22% while AUC was similar
following co&#8209;administration of Erleada as a 240&nbsp;mg single dose with
itraconazole (strong CYP3A4 inhibitor). For the active moieties (sum of
apalutamide plus the potency adjusted active metabolite), C<sub>max</sub>
decreased by 22% while AUC was again similar. No initial dose adjustment is
necessary when Erleada is co&#8209;administered with a strong inhibitor of
CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) however, a reduction of the
Erleada dose based on tolerability should be considered <span lang=EN-GB>(see
section&nbsp;4.2)</span>. Mild or moderate inhibitors of CYP3A4 are not
expected to affect the exposure of apalutamide.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Medicinal products that
induce CYP3A4 or CYP2C8</i></p>

<p class=MsoNormal>The effects of CYP3A4 or CYP2C8 inducers on the
pharmacokinetics of apalutamide have not been evaluated <i>in vivo</i>. Based
on the drug-drug interaction study results with strong CYP3A4 inhibitor or
strong CYP2C8 inhibitor, CYP3A4 or CYP2C8 inducers are not expected to have
clinically relevant effects on the pharmacokinetics of apalutamide and the
active moieties therefore no dose adjustment is necessary when Erleada is
co-administered with inducers of CYP3A4 or CYP2C8.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Potential for apalutamide
to affect exposures to other medicinal products</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>Apalutamide is a potent enzyme inducer and increases the
synthesis of many enzymes and transporters; therefore, interaction with many
common medicinal products that are substrates of enzymes or transporters is
expected. The reduction in plasma concentrations can be substantial, and lead
to lost or reduced clinical effect. There is also a risk of increased formation
of active metabolites.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Drug metabolising enzymes</i></p>

<p class=MsoNormal><i>In vitro</i> studies showed that apalutamide and N&#8209;desmethyl
apalutamide are moderate to strong CYP3A4 and CYP2B6 inducers, are moderate
inhibitors of CYP2B6 and CYP2C8, and weak inhibitors of CYP2C9, CYP2C19, and
CYP3A4. Apalutamide and N&#8209;desmethyl apalutamide do not affect CYP1A2 and
CYP2D6 at therapeutically relevant concentrations. The effect of apalutamide on
CYP2B6 substrates has not been evaluated <i>in vivo</i> and the net effect is
presently unknown. When substrates of CYP2B6 (e.g., efavirenz) are administered
with Erleada, monitoring for an adverse reaction and evaluation for loss of
efficacy of the substrate should be performed and dose adjustment of the
substrate may be required to maintain optimal plasma concentrations.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In humans, apalutamide is a strong inducer of CYP3A4 and
CYP2C19, and a weak inducer of CYP2C9. In a drug&#8209;drug interaction study
using a cocktail approach, co&#8209;administration of apalutamide with single
oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of
midazolam (CYP3A4 substrate), 85% decrease in the AUC of omeprazole (CYP2C19
substrate), and 46% decrease in the AUC of S&#8209;warfarin (CYP2C9 substrate).
Apalutamide did not cause clinically meaningful changes in exposure to the
CYP2C8 substrate. Concomitant use of Erleada with medicinal products that are
primarily metabolised by CYP3A4 (e.g., darunavir, felodipine, midazolam,
simvastatin), CYP2C19 (e.g., diazepam, omeprazole), or CYP2C9 (e.g., warfarin,
phenytoin) can result in lower exposure to these medicinal products.
Substitution for these medicinal products is recommended when possible or
evaluation for loss of efficacy should be performed if the medicinal product is
continued. If given with warfarin, INR should be monitored during Erleada
treatment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Induction of CYP3A4 by apalutamide suggests that UDP&#8209;glucuronosyl
transferase (UGT) may also be induced via activation of the nuclear pregnane X
receptor (PXR). Concomitant administration of Erleada with medicinal products that
are substrates of UGT (e.g., levothyroxine, valproic acid) can result in lower
exposure to these medicinal products. When substrates of UGT are co&#8209;administered
with Erleada, evaluation for loss of efficacy of the substrate should be
performed and dose adjustment of the substrate may be required to maintain
optimal plasma concentrations.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Drug transporters</i></p>

<p class=MsoNormal>Apalutamide was shown to be a weak inducer of P&#8209;glycoprotein
(P&#8209;gp), breast cancer resistance protein (BCRP), and organic anion
transporting polypeptide 1B1 (OATP1B1) clinically. A drug&#8209;drug
interaction study using a cocktail approach showed that co&#8209;administration
of apalutamide with single oral doses of sensitive transporter substrates
resulted in a 30% decrease in the AUC of fexofenadine (P&#8209;gp substrate)
and 41% decrease in the AUC of rosuvastatin (BCRP/OATP1B1 substrate) but had no
impact on C<sub>max</sub>. Concomitant use of Erleada with medicinal products that
are substrates of P&#8209;gp (e.g., colchicine, dabigatran etexilate, digoxin),
BCRP or OATP1B1 (e.g., lapatinib, methotrexate, rosuvastatin, repaglinide) can
result in lower exposure of these medicinal products. When substrates of P&#8209;gp,
BCRP or OATP1B1 are co&#8209;administered with Erleada, evaluation for loss of
efficacy of the substrate should be performed and dose adjustment of the
substrate may be required to maintain optimal plasma concentrations.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Based on <i>in vitro</i> data, inhibition of organic cation
transporter&nbsp;2 (OCT2), organic anion transporter&nbsp;3 (OAT3) and
multidrug and toxin extrusions (MATEs) by apalutamide and its N&#8209;desmethyl
metabolite cannot be excluded. No <i>in vitro</i> inhibition of organic anion
transporter 1 (OAT1) was observed.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>GnRH Analog</i></p>

<p class=MsoNormal>In mHSPC subjects receiving leuprolide acetate (a GnRH
analog), co-administration with apalutamide had no apparent effect on the
steady-state exposure of leuprolide.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Medicinal products which
prolong the QT interval</u></p>

<p class=MsoNormal>Since androgen deprivation treatment may prolong the QT
interval, the concomitant use of Erleada with medicinal products known to
prolong the QT interval or medicinal products able to induce Torsade de pointes
such as class IA (e.g., quinidine, disopyramide) or class III (e.g.,
amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products,
methadone, moxifloxacin, antipsychotics (e.g. haloperidol), etc. should be
carefully evaluated (see section 4.4).</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Interaction studies have only been
performed in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp; Fertility, pregnancy and
lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Contraception
in males and females</span></u></p>

<p class=MsoNormal><a name="_Hlk501043871"><span lang=EN-GB>It is not known
whether apalutamide or its metabolites are present in semen. </span></a>Erleada
may be harmful to a developing foetus. For patients having sex with female
partners of reproductive potential, a condom should be used along with another
highly effective contraceptive method during treatment and for 3&nbsp;months
after the last dose of Erleada.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal>Erleada is contraindicated in women who are or may become
pregnant (see section&nbsp;4.3). Based on its mechanism of action, Erleada may
cause foetal harm when administered during pregnancy. There are no data
available from the use of Erleada in pregnant women. Animal reproductive
studies have not been conducted with Erleada.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether apalutamide/metabolites
are excreted in human milk. A risk to the suckling child cannot be excluded.
Erleada should not be used during breast-feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Based on animal studies, Erleada may decrease
fertility in males of reproductive potential (see section&nbsp;5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp; Effects on ability to drive
and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada has no or negligible influence on
the ability to drive and use machines. However, seizures have been reported in
patients taking Erleada. Patients should be advised of this risk in regards to
driving or operating machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The most common
adverse reactions are fatigue (26%), skin rash (26% of any grade and 6% Grade 3
or 4), hypertension (22%), hot flush (18%), arthralgia (17%), diarrhoea (16%), fall
(13%), and weight decreased (13%). Other important adverse reactions include
fractures (11%) and hypothyroidism (8%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions observed during clinical
studies are listed below by frequency category. Frequency categories are
defined as follows: very common (&#8805;&nbsp;1/10); common (&#8805;&nbsp;1/100
to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000)
and not known (frequency cannot be estimated from the available data).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Within each frequency grouping, undesirable
effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;border-bottom:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions
  identified in clinical studies</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>System organ class</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Adverse reaction and frequency<sup>a</sup> </span></b></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Endocrine
  disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: hypothyroidism<sup>b</sup></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.65pt'>
  <td width=292 rowspan=2 valign=top style='width:219.2pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Metabolism
  and nutrition disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common:
  decreased appetite</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.6pt'>
  <td width=311 valign=top style='width:233.2pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.6pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: hypercholesterolaemia,
  hypertriglyceridaemia</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Nervous
  system disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: dysgeusia,
  ischaemic cerebrovascular disorders<sup>c</sup></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>uncommon: seizure</span><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:10.0pt'> (see
  section&nbsp;4.4)</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 rowspan=2 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Cardiac
  disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: ischaemic
  heart disease<sup>e</sup></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>not known: QT
  prolongation (see sections 4.4 and 4.5)</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Vascular
  disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: hot
  flush, hypertension</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common:
  diarrhoea</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: skin
  rash<sup>f</sup></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:5.65pt'>
  <td width=292 rowspan=2 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: pruritus,
  alopecia</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:5.6pt'>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.6pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>not known: toxic
  epidermal necrolysis</span><sup><span lang=EN-GB>g</span></sup></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Musculoskeletal
  and connective tissue disorders</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: fracture<sup>h</sup>,
  arthralgia</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>common: muscle
  spasm</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>General
  disorders and administration site conditions</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: fatigue</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Investigations</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: weight
  decreased</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:219.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Injury,
  poisoning and procedural complications</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>very common: fall</span></p>
  </td>
  <td style='border:none;border-bottom:solid black 1.0pt' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  style='font-size:9.0pt'>Adverse reaction frequencies presented are based on
  the placebo&#8209;controlled period of the clinical studies</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Includes hypothyroidism, blood thyroid
  stimulating hormone increased, thyroxine decreased, autoimmune thyroiditis,
  thyroxine free decreased, tri&#8209;iodothyronine decreased</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Includes transient ischaemic attack,
  cerebrovascular accident, cerebrovascular disorder, ischaemic stroke, carotid
  arteriosclerosis, carotid artery stenosis, hemiparesis, lacunar infarction,
  lacunar stroke, thrombotic cerebral infarction, vascular encephalopathy,
  cerebellar infarction, cerebral infarction, and cerebral ischaemia</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Includes tongue biting</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Includes angina pectoris, angina unstable,
  myocardial infarction, acute myocardial infarction, coronary artery
  occlusion, coronary artery stenosis, acute coronary syndrome,
  arteriosclerosis coronary artery, cardiac stress test abnormal, troponin
  increased, myocardial ischaemia</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>f</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>See &#8220;Skin rash&#8221; under
  &#8220;Description of selected adverse reactions&#8221;</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>g</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Post-marketing adverse reaction</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>h</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Includes rib fracture, lumbar vertebral
  fracture, spinal compression fracture, spinal fracture, foot fracture, hip
  fracture, humerus fracture, thoracic vertebral fracture, upper limb fracture,
  fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle
  fracture, compression fracture, costal cartilage fracture, facial bones
  fracture, lower limb fracture, osteoporotic fracture, wrist fracture,
  avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, radius
  fracture, sternal fracture, stress fracture, traumatic fracture, cervical
  vertebral fracture, femoral neck fracture, tibia fracture. See below.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Skin rash</span></i></p>

<p class=MsoNormal style='text-autospace:none'>Skin rash associated with apalutamide
was most commonly described as macular or maculo&#8209;papular. Skin rash
included rash, rash maculo<span lang=EN-GB style='font-size:9.0pt'>&#8209;</span>papular,
rash generalised, urticaria, rash pruritic, rash macular, conjunctivitis,
erythema multiforme, rash papular, skin exfoliation, genital rash, rash
erythematous, stomatitis, drug eruption, mouth ulceration, rash pustular,
blister, papule, pemphigoid, skin erosion, dermatitis, and rash vesicular. Adverse
reactions of skin rash were reported for 26% of patients treated with apalutamide.
Grade&nbsp;3 skin rashes (defined as covering <a name="_Hlk494288965">&gt;</a>&nbsp;30%
body surface area [BSA]) were reported with apalutamide treatment in 6% of
patients.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The median days to onset of skin
rash was 83&nbsp;days. Seventy-eight percent of patients had resolution of rash
with a median of 78 days to resolution.&nbsp; Medicinal products utilised included
topical corticosteroids, oral anti-histamines, and 19% of patients received systemic
corticosteroids. Among patients with skin rash, dose interruption occurred in
28% and dose reduction occurred in 14% (see section&nbsp;4.2). Skin rash
recurred in 59% of patients who had dose interruption. Skin rash led to apalutamide
treatment discontinuation in 7% of patients who experienced skin rash.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Falls and fractures</span></i></p>

<p class=MsoNormal style='text-autospace:none'>In Study&nbsp;ARN&#8209;509&#8209;003,
fracture was reported for 11.7% of patients treated with apalutamide and 6.5%
of patients treated with placebo. Half of the patients experienced a fall
within 7&nbsp;days before the fracture event in both treatment groups. Falls
were reported for 15.6% of patients treated with apalutamide <i>versus</i> 9.0%
of patients treated with placebo (see section 4.4).</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Ischaemic heart disease and ischaemic cerebrovascular disorders</span></i></p>

<p class=MsoNormal>In a randomised study (SPARTAN) of patients with nmCRPC,
ischaemic heart disease occurred in 4% of patients treated with apalutamide and
3% of patients treated with placebo. In a randomised study (TITAN) in patients
with mHSPC, ischaemic heart disease occurred in 4% of patients treated with
apalutamide and 2% of patients treated with placebo. Across the SPARTAN and
TITAN studies, 6&nbsp;patients (0.5%) treated with apalutamide and 2&nbsp;patients
(0.2%) treated with placebo died from ischaemic heart disease (see section
4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In the SPARTAN study, with a median exposure of
32.9&nbsp;months for apalutamide and 11.5&nbsp;months for placebo, ischaemic
cerebrovascular disorders occurred in 4% of patients treated with apalutamide
and 1% of patients treated with placebo (see above). In the TITAN study, <span
lang=EN-GB>ischaemic cerebrovascular disorders occurred in a similar proportion
of patients in the apalutamide (1.5%) and placebo (1.5%) groups. </span>Across
the SPARTAN and TITAN studies, 2&nbsp;patients (0.2%) treated with apalutamide
and no patients treated with placebo died from an ischaemic cerebrovascular
disorder (see section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i>Hypothyroidism</i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'>Hypothyroidism was reported for 8% of patients treated
with apalutamide and 2% of patients treated with placebo based on assessments
of thyroid&#8209;stimulating hormone (TSH) every 4&nbsp;months. There were no
grade&nbsp;3 or 4 adverse events. Hypothyroidism occurred in 30% of patients
already receiving thyroid replacement therapy in the apalutamide arm and in 3%
of patients in the placebo arm. In patients not receiving thyroid replacement
therapy, hypothyroidism occurred in 7% of patients treated with apalutamide and
in 2% of patients treated with placebo. Thyroid replacement therapy, when
clinically indicated, should be initiated or dose&#8209;adjusted (see section&nbsp;4.5).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions
via <span lang=EN-GB style='background:silver'>the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>There is no known specific antidote for apalutamide
overdose. In the event of an overdose, Erleada should be stopped and general
supportive measures should be undertaken until clinical toxicity has been
diminished or resolved. Adverse reactions in the event of an overdose has not
yet been observed, it is expected that such reactions would resemble the
adverse reactions listed in section 4.8.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Endocrine
therapy, anti-androgens</span><span lang=EN-GB>, ATC code: L02BB05</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='text-autospace:none'>Apalutamide is an orally
administered, selective Androgen Receptor (AR) inhibitor that binds directly to
the ligand&#8209;binding domain of the AR. Apalutamide prevents AR nuclear
translocation, inhibits DNA binding, impedes AR&#8209;mediated transcription,
and lacks androgen receptor agonist activity. Apalutamide treatment decreases
tumor cell proliferation and increases apoptosis leading to potent antitumor
activity. A major metabolite, N&#8209;desmethyl apalutamide, exhibited one&#8209;third
the <i>in vitro</i> activity of apalutamide.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Cardiac electrophysiology</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The effect of
apalutamide 240 mg once daily on the QTc interval was assessed in an
open-label, uncontrolled, multi-center, single-arm dedicated QT study in 45
patients with CRPC. At steady-state, the maximum mean QTcF change from baseline
was 12.4 ms (2-sided 90% upper CI: 16.0 ms). An exposure-QT analysis suggested
a concentration-dependent increase in QTcF for apalutamide and its active
metabolite.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The efficacy
and safety of apalutamide has been established in two Phase 3 randomised, placebo-controlled
studies, Study ARN-509-003 (nmCRPC) and 56021927PCR3002 (mHSPC).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u>TITAN:
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)</u></i></p>

<p class=MsoNormal style='text-autospace:none'>TITAN was a randomised,
double-blind, placebo-controlled, multinational, multicenter clinical trial in
which 1052 patients with mHSPC were randomised (1:1) to receive either apalutamide
orally at a dose of 240<a name="_Hlk2607508">&nbsp;</a>mg once daily (N&nbsp;=&nbsp;525)
or placebo once daily (N&nbsp;=&nbsp;527). <span lang=EN-GB>All patients were
required to have at least one bone metastasis on </span><span lang=EN-GB
style='color:#222222;background:white'>Technetium</span><span lang=EN-GB
style='color:#222222;background:white'>&nbsp;<sup>99m</sup></span><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;color:#222222;
background:white'> </span><span lang=EN-GB>bone scan. Patients were excluded if
the site of metastases was limited to <span style='color:black'>either the
lymph </span>nodes or viscera (e.g., liver or lung). </span>All patients in the
TITAN trial received concomitant GnRH analog or had prior bilateral
orchiectomy. <span lang=EN-GB>Around 11% of patients received prior treatment
with docetaxel (maximum of 6 cycles, last dose &#8804;2 months prior to
randomisation and maintained response prior to randomisation). The exclusion
criteria included known brain metastases; prior treatment with other next
generation anti-androgens (eg, enzalutamide), CYP17 inhibitors (eg, abiraterone
acetate), immunotherapy (eg, sipuleucel-T), radiopharmaceutical agents or other
treatments for prostate cancer; or history of seizure or condition that may
predispose to seizure. </span>Patients were stratified by Gleason score at
diagnosis, prior docetaxel use, and region of the world. Patients with both
high- and low-volume mHSPC were eligible for the study.<span lang=EN-GB>
High-volume disease was defined as either visceral metastases and at least 1
bone lesion or at least 4 bone lesions, with at least 1 bone lesion outside of
the vertebral column or pelvis. Low-volume disease was defined as the presence
of bone lesion(s) not meeting the definition of high-volume.</span></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The following patient
demographics and baseline disease characteristics were balanced between the
treatment arms. The median age was 68&nbsp;years (range 43-94) and 23% of
patients were 75&nbsp;years of age or older. The racial distribution was 68%
Caucasian, 22% Asian, and 2% Black. Sixty-three percent (63%) of patients had
high-volume disease and 37% had low-volume disease. Sixteen percent (16%) of
patients had prior surgery, radiotherapy of the prostate or both. A majority of
patients had a Gleason score of 7 or higher (92%). Sixty-eight percent (68%) of
patients received prior treatment with a first-generation anti-androgen in the
non-metastatic setting. <span lang=EN-GB>Although criteria for castration
resistance were not determined at baseline, 94% of patients demonstrated a
decrease in <a name="_Hlk26781894">prostate specific antigen </a>(PSA) from
initiation of <a name="_Hlk26781940">androgen deprivation therapy </a>(ADT) to
first dose of apalutamide or placebo. </span>All patients except one in the
placebo group, had an Eastern Cooperative Oncology Group Performance Status
(ECOG PS) score of 0 or 1 at study entry. Among the patients who discontinued
study treatment (N&nbsp;=&nbsp;271 for placebo and N&nbsp;=&nbsp;170 for Erleada),
the most common reason for discontinuation in both arms was disease
progression. A greater proportion (73%) of patients treated with placebo
received subsequent anti-cancer therapy compared to patients treated with Erleada
(54%). </p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The major efficacy outcome
measures of the study were overall survival (OS) and radiographic
progression-free survival (rPFS). Efficacy results of TITAN are summarised in
Table 2 and Figures 1 and 2.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=631
 style='border-collapse:collapse;border:none'>
 <tr style='height:19.3pt'>
  <td width=631 colspan=3 style='width:473.4pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  style='font-size:10.0pt'>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary
  of Efficacy Results &#8211; Intent-to-treat mHSPC Population (TITAN)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=360 style='width:3.75in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  style='font-size:10.0pt'>Endpoint</span></b></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span style='font-size:10.0pt'>Erleada</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span style='font-size:10.0pt'>N=525</span></b></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span style='font-size:10.0pt'>Placebo</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span style='font-size:10.0pt'>N=527</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  style='font-size:10.0pt'>Overall Survival </span></b></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Deaths
  (%)</span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>83 (16%)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>117 (22%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Median,
  months (95% CI)</span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>NE (NE, NE)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>NE (NE, NE)</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Hazard
  ratio (95% CI)<sup>a</sup></span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>0.671 (0.507, 0.890)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>p-value<sup>b</sup></span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>0.0053</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  style='font-size:10.0pt'>Radiographic Progression-free Survival </span></b></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Disease
  progression or death (%)</span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>134 (26%)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>231 (44%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Median,
  months (95% CI)</span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>NE (NE, NE)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>22.08 (18.46, 32.92)</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Hazard
  ratio (95% CI)<sup>a</sup></span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>0.484 (0.391, 0.600)</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>p-value<sup>b</sup></span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>&lt;.0001</span></p>
  </td>
  <td width=131 valign=top style='width:98.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=631 colspan=3 valign=top style='width:473.4pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid;text-autospace:none'><sup>a</sup>&nbsp;&nbsp;&nbsp; <span
  style='font-size:9.0pt'>Hazard ratio is from stratified proportional hazards
  model. Hazard ratio &lt;1 favors active treatment.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid;text-autospace:none'><sup>b</sup>&nbsp;&nbsp;&nbsp; <span
  style='font-size:9.0pt'>p-value is from the log-rank test stratified by
  Gleason score at diagnosis (&#8804;7 vs. &gt;7), Region (NA/EU vs. Other
  Countries) and Prior docetaxel use (Yes vs. No).</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:9.0pt'>NE=Not Estimable</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>A statistically significant
improvement in OS and rPFS was demonstrated in patients randomised to receive Erleada
compared with patients randomised to receive placebo. Consistent improvement in
rPFS was observed across patient subgroups including high- or low-volume
disease, prior docetaxel use (yes or no), age (&lt; 65, &#8805;65, or &#8805;75
years old), baseline PSA above median (yes or no), and number of bone lesions
(&#8804;10 or &gt;10). </p>

<p class=MsoNormal style='text-autospace:none'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:56.9pt;text-indent:-56.9pt;page-break-after:
avoid;text-autospace:none'><b>Figure 1:&nbsp;&nbsp;&nbsp; Kaplan-Meier Plot of
Overall Survival (OS); Intent-to-treat mHSPC Population (TITAN)</b></p>

<p class=MsoNormal style='text-autospace:none'><img border=0 width=591
height=510 id="Picture 18"
src="Erleada-II-009%20EN%20PI%20Clea_files/image002.gif"></p>

<p class=MsoNormal style='text-autospace:none'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:56.9pt;text-indent:-56.9pt;page-break-after:
avoid;text-autospace:none'><b>Figure 2:&nbsp;&nbsp;&nbsp; Kaplan-Meier Plot of
Radiographic Progression-Free Survival (rPFS); Intent-to-treat mHSPC Population
(TITAN)</b></p>

<p class=MsoNormal style='text-autospace:none'><img border=0 width=579
height=500 id="Picture 11"
src="Erleada-II-009%20EN%20PI%20Clea_files/image003.gif"></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>Treatment with Erleada
statistically significantly delayed the initiation of cytotoxic chemotherapy
(HR&nbsp;=&nbsp;0.391, CI&nbsp;=&nbsp;0.274, 0.558; p&nbsp;&lt;&nbsp;0.0001),
resulting in a 61% reduction of risk for subjects in the treatment arm compared
to the placebo arm.</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u><span
lang=EN-GB>SPARTAN: Non-Metastatic Castration Resistant Prostate Cancer
(nmCRPC)</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'>A total of 1207&nbsp;subjects
with NM&#8209;CRPC were randomised 2:1 to receive either apalutamide orally at
a dose of 240&nbsp;mg once daily in combination with androgen deprivation
therapy (ADT) (medical castration or prior surgical castration) or placebo with
ADT in a multicenter, double&#8209;blind, clinical study (Study&nbsp;ARN&#8209;509&#8209;003).
Subjects enrolled had a Prostate Specific Antigen (PSA) Doubling Time (PSADT)
&#8804;&nbsp;10&nbsp;months, considered to be at high risk of imminent
metastatic disease and prostate cancer&#8209;specific death. All subjects who
were not surgically castrated received ADT continuously throughout the study. PSA
results were blinded and were not used for treatment discontinuation. Subjects
randomised to either arm were to continue treatment until disease progression
defined by blinded central imaging review (BICR), initiation of new treatment,
unacceptable toxicity or withdrawal. </p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The following patient
demographics and baseline disease characteristics were balanced between the
treatment arms. The median age was 74&nbsp;years (range&nbsp;48&#8209;97) and
26% of subjects were 80&nbsp;years of age or older. The racial distribution was
66% Caucasian, 5.6% Black, 12% Asian, and 0.2% Other. Seventy&#8209;seven
percent (77%) of subjects in both treatment arms had prior surgery or
radiotherapy of the prostate. A majority of subjects had a Gleason score of 7
or higher (81%). Fifteen percent (15%) of subjects had &lt;&nbsp;2&nbsp;cm
pelvic lymph nodes at study entry. Seventy&#8209;three percent (73%) of
subjects received prior treatment with a first generation anti&#8209;androgen;
69% of subjects received bicalutamide and 10% of subjects received flutamide. All
subjects enrolled were confirmed to be non&#8209;metastatic by blinded central
imaging review and had an Eastern Cooperative Oncology Group Performance Status
(ECOG PS) performance status score of 0 or 1 at study entry.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><a name="_Hlk526253475">Metastasis&#8209;free
survival (MFS) was the primary endpoint, defined as the time from randomisation
to the time of first evidence of BICR&#8209;confirmed bone or soft tissue
distant metastasis or death due to any cause, whichever occurred first.
Treatment with Erleada significantly improved MFS. Erleada decreased the relative
risk of distant metastasis or death by 70% compared to placebo (HR&nbsp;=&nbsp;0.30;
95% CI: 0.24, 0.36; p&nbsp;&lt;&nbsp;0.0001). The median MFS for Erleada was 41&nbsp;months
and was 16&nbsp;months for placebo (see Figure&nbsp;3). Consistent improvement in
MFS with Erleada was observed for all pre-specified subgroups, including age,
race, region of the world, nodal status, prior number of hormonal therapies,
baseline PSA, PSA doubling time, baseline ECOG status and use of bone-sparing
agents.</a></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b>Figure&nbsp;3:&nbsp;&nbsp;&nbsp; Kaplan&#8209;Meier
metastasis&#8209;free survival (MFS) curve in Study&nbsp;ARN-509-003</b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:9.0pt'><img border=0 width=615 height=431
src="Erleada-II-009%20EN%20PI%20Clea_files/image004.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><a name=IDX></a>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>Taking account of all data, subjects
treated with Erleada and ADT showed significant improvement over those treated
with ADT alone for the following secondary endpoints of time to metastasis (HR&nbsp;<span
lang=EN-GB>=</span>&nbsp;0.28; 95% CI: 0.23, 0.34; p&nbsp;&lt;&nbsp;0.0001), progression&#8209;free
survival (PFS) (HR&nbsp;<span lang=EN-GB>=</span>&nbsp;0.30; 95% CI: 0.25, 0.36;
p&nbsp;&lt;&nbsp;0.0001); time to symptomatic progression (<a
name="_Hlk526253220">HR&nbsp;</a><span lang=EN-GB>=</span>&nbsp;0.57; 95% CI:&nbsp;0.44,
0.73; p&nbsp;&lt;&nbsp;0.0001); overall survival (OS) (HR&nbsp;<span
lang=EN-GB>=</span>&nbsp;0.78; 95% CI:&nbsp;0.64, 0.96; p&nbsp;=&nbsp;0.0161)
and time to initiation of cytotoxic chemotherapy (HR&nbsp;=&nbsp;0.63; 95% CI:
0.49, 0.81; p&nbsp;=&nbsp;0.0002).</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>Time to symptomatic progression
was defined as time from randomization to development of a skeletal related
event, pain/symptoms requiring initiation of a new systemic anti-cancer
therapy, or loco-regional tumor progression requiring radiation/surgery. While
the overall number of events was small, the difference between the two arms was
sufficiently large to reach statistical significance. Treatment with Erleada
decreased the risk of symptomatic progression by 43% compared with placebo
(HR=0.567; 95% CI: 0.443, 0.725; p&nbsp;&lt;&nbsp;0.0001). The median time to
symptomatic progression was not reached in either treatment group.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>W</span><span
lang=EN-GB>ith median follow-up time of 52.0&nbsp;months, results showed that treatment
with Erleada significantly decreased the risk of death by 22% compared with
placebo (HR&nbsp;=&nbsp;0.784; 95% CI: 0.643, 0.956; 2&#8209;sided p&nbsp;=&nbsp;0.0161).
The median OS was 73.9&nbsp;months for the Erleada arm and 59.9&nbsp;months for
the placebo arm. The pre-specified alpha boundary (p&nbsp;&#8804;&nbsp;0.046)
was crossed and statistical significance was achieved. This improvement was
demonstrated even though 19% of patients in the placebo arm received Erleada as
subsequent therapy.</span></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b>Figure&nbsp;4:&nbsp;&nbsp;&nbsp; Kaplan&#8209;Meier
overall survival (OS) curve in Study&nbsp;ARN-509-003 at final analysis</b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:9.0pt;font-family:"Times",serif;color:black'><img border=0
width=565 height=397 src="Erleada-II-009%20EN%20PI%20Clea_files/image005.jpg"
alt="A close up of a map&#13;&#10;&#13;&#10;Description automatically generated"></span></p>

<p class=MsoNormal style='text-autospace:none'><a name="_Hlk37427350">Treatment
with Erleada significantly decreased the risk of initiating cytotoxic
chemotherapy by 37% compared with placebo (HR&nbsp;=&nbsp;0.629; 95% CI: 0.489,
0.808; p&nbsp;=&nbsp;0.0002) demonstrating statisically significant improvement
for Erleada versus placebo. The median time to the initiation of cytotoxic
chemotherapy was not reached for either treatment arm.</a></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>PFS&#8209;2, defined as the time
to death or disease progression by PSA, radiographic, or symptomatic
progression on or after first subsequent therapy was longer for subjects
treated with Erleada compared to those treated with placebo. Results
demonstrated a 44% reduction in risk of PFS-2 with Erleada versus placebo
(HR&nbsp;=&nbsp;0.565, 95% CI: 0.471, 0.677; p&nbsp;&lt;&nbsp;0.0001).</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There were no detrimental
effects to overall health-related quality of life with the adddition of Erleada
to ADT and a small but not clinically meaningful difference in change from
baseline in favor of Erleada observed in the analysis of the Functional
Assessment of Cancer Therapy&#8209;Prostate (FACT&#8209;P) total score and
subscales.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with Erleada in all subsets of
the paediatric population in advanced prostate cancer. See section&nbsp;4.2 for
information on paediatric use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Following repeat once&#8209;daily dosing, apalutamide
exposure (C<sub>max</sub> and area under the concentration curve [AUC])
increased in a dose&#8209;proportional manner across the dose range of 30 to 480&nbsp;mg.
Following administration of 240&nbsp;mg once daily, apalutamide steady state
was achieved after 4&nbsp;weeks and the mean accumulation ratio was
approximately 5&#8209;fold relative to a single dose. At steady&#8209;state,
mean (CV%) C<sub>max</sub> and AUC values for apalutamide were 6&nbsp;&micro;g/mL
(28%) and 100&nbsp;&micro;g.h/mL (32%), respectively. Daily fluctuations in
apalutamide plasma concentrations were low, with mean peak&#8209;to&#8209;trough
ratio of 1.63. An increase in apparent clearance (CL/F) was observed with repeat
dosing, likely due to induction of apalutamide&#8217;s own metabolism.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>At steady&#8209;state, the mean (CV%) C<sub>max</sub> and
AUC values for the major active metabolite, N&#8209;desmethyl apalutamide, were
5.9&nbsp;&micro;g/mL (18%) and 124&nbsp;<a name="_Hlk493511689">&micro;</a>g.h/mL
(19%), respectively. N&#8209;desmethyl apalutamide is characterised by a flat
concentration&#8209;time profile at steady&#8209;state with a mean peak&#8209;to&#8209;trough
ratio of 1.27. Mean (CV%) AUC metabolite/parent drug ratio for N&#8209;desmethyl
apalutamide following repeat&#8209;dose administration was about 1.3 (21%).
Based on systemic exposure, relative potency, and pharmacokinetic properties, N&#8209;desmethyl
apalutamide likely contributed to the clinical activity of apalutamide.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal>After oral administration, median time to achieve peak
plasma concentration (t<sub>max</sub>) was 2&nbsp;hours (range: 1 to 5&nbsp;hours).
Mean absolute oral bioavailability is approximately 100%, indicating that
apalutamide is completely absorbed after oral administration.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Administration of apalutamide to healthy subjects under
fasting conditions and with a high&#8209;fat meal resulted in no clinically
relevant changes in C<sub>max</sub> and AUC. Median time to reach t<sub>max</sub>
was delayed about 2&nbsp;hours with food (see section&nbsp;4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><a name="_Hlk518395309">Apalutamide is not ionizable under
relevant physiological pH condition, therefore acid lowering agents (e.g.,
proton pump inhibitor, H<sub>2</sub>&#8209;receptor antagonist, antacid) are
not expected to affect the solubility and bioavailability of apalutamide.</a></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><i>In vitro</i>, apalutamide and its N&#8209;desmethyl
metabolite are substrates for P&#8209;gp. Because apalutamide is completely absorbed
after oral administration, P&#8209;gp does not limit the absorption of
apalutamide and therefore, inhibition or induction of P&#8209;gp is not
expected to affect the bioavailability of apalutamide.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal>The mean apparent volume of distribution at steady&#8209;state
of apalutamide is about 276&nbsp;L. The volume of distribution of apalutamide
is greater than the volume of total body water, indicative of extensive
extravascular distribution.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Apalutamide and N&#8209;desmethyl apalutamide are 96% and
95% bound to plasma proteins, respectively, and mainly bind to serum albumin
with no concentration dependency.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal>Following single oral administration of <sup>14</sup>C&#8209;labeled
apalutamide 240&nbsp;mg, apalutamide, the active metabolite, N&#8209;desmethyl
apalutamide, and an inactive carboxylic acid metabolite accounted for the
majority of the <sup>14</sup>C&#8209;radioactivity in plasma, representing 45%,
44%, and 3%, respectively, of the total <sup>14</sup>C&#8209;AUC.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Metabolism is the main route of elimination of apalutamide.
It is metabolised primarily by CYP2C8 and CYP3A4 to form N&#8209;desmethyl
apalutamide. Apalutamide and N&#8209;desmethyl apalutamide are further metabolised
to form the inactive carboxylic acid metabolite by carboxylesterase. The
contribution of CYP2C8 and CYP3A4 in the metabolism of apalutamide is estimated
to be 58% and 13% following single dose but the level of contribution is
expected to change at steady&#8209;state due to induction of CYP3A4 by
apalutamide after repeat dose.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal>Apalutamide, mainly in the form of metabolites, is
eliminated primarily via urine. Following a single oral administration of
radiolabeled apalutamide, 89% of the radioactivity was recovered up to 70&nbsp;days
post&#8209;dose: 65% was recovered in urine (1.2% of dose as unchanged
apalutamide and 2.7% as N&#8209;desmethyl apalutamide) and 24% was recovered in
feces (1.5% of dose as unchanged apalutamide and 2% as N&#8209;desmethyl
apalutamide).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The apparent oral clearance (CL/F) of apalutamide is 1.3&nbsp;L/h
after single dosing and increases to 2.0&nbsp;L/h at steady&#8209;state after
once&#8209;daily dosing. The mean effective half&#8209;life for apalutamide in
patients is about 3&nbsp;days at steady&#8209;state.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i> data indicate that apalutamide and its N&#8209;desmethyl
metabolite are not substrates for BCRP, OATP1B1 or OATP1B3.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The effects of renal impairment, hepatic
impairment, age, race, and other extrinsic factors on the pharmacokinetics of
apalutamide are summarised below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Renal
impairment</span></u></i></p>

<p class=MsoNormal>A dedicated renal impairment study for apalutamide has not
been conducted. Based on the population pharmacokinetic analysis using data
from clinical studies in subjects with castration&#8209;resistant prostate
cancer (CRPC) and healthy subjects, no significant difference in systemic apalutamide
exposure was observed in subjects with pre&#8209;existing mild to moderate
renal impairment (estimated glomerular filtration rate [eGFR] between 30 to 89&nbsp;mL/min/1.73&nbsp;m<sup>2</sup><sub>;
</sub>N=585) compared to subjects with baseline normal renal function
(eGFR&nbsp;&#8805;&nbsp;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup><sub>; </sub>N=372).
<span lang=EN-GB>The potential effect of severe renal impairment or end stage
renal disease (eGFR&nbsp;&#8804;29&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) have
not been established due to insufficient data.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Hepatic
impairment</span></u></i></p>

<p class=MsoNormal>A dedicated hepatic impairment study compared the systemic
exposure of apalutamide and N&#8209; desmethyl apalutamide in subjects with
baseline mild hepatic impairment (N=8, Child&#8209;Pugh Class A, mean score =
5.3) or moderate hepatic impairment (N=8, Child&#8209;Pugh Class B, mean score
= 7.6) <i>versus</i> healthy controls with normal hepatic function (N=8). Following
a single oral 240&nbsp;mg dose of apalutamide, the geometric mean ratio (GMR)
for AUC and C<sub>max</sub> for apalutamide in subjects with mild impairment
was 95% and 102%, respectively, and the GMR for AUC and C<sub>max</sub> of
apalutamide in subjects with moderate impairment was 113% and 104%,
respectively, compared to healthy control subjects. Clinical and
pharmacokinetic data for apalutamide are not available for patients with severe
hepatic impairment (Child&#8209;Pugh Class C).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Ethnicity
and race</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Based on population pharmacokinetic
analysis, there were no clinically relevant differences in apalutamide
pharmacokinetics between White (Caucasian or Hispanic or Latino; N=761), Black
(of African heritage or African American; N=71), Asian (non&#8209;Japanese;
N=58) and Japanese (N=58).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Age</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analyses showed
that age (range: 18 to 94&nbsp;years) does not have a clinically meaningful
influence on the pharmacokinetics of apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Toc128303703"></a><a name="_Toc128305228"></a><a
name="_Toc128305461"></a><a name="_Toc128306676"></a><a name="_Toc128307804"></a><a
name="_Toc128307954"></a><a name="_Toc138496810"></a><a name="_Toc147561380">Apalutamide
<span lang=EN-GB>was negative for genotoxicity in a standard battery of <i>in&nbsp;vitro</i>
and <i>in&nbsp;vivo</i> tests.</span></a></p>

<p class=MsoNormal>Apalutamide was not carcinogenic in a 6-month study in the
male transgenic (Tg.rasH2) mouse at doses up to 30&nbsp;mg/kg per day, which is
1.2 and 0.5&nbsp;times for apalutamide and N&#8209;desmethyl apalutamide
respectively, the clinical exposure (AUC) at the recommended clinical dose of
240&nbsp;mg/day.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Male fertility is likely to be impaired by treatment with
apalutamide based on findings in repeat&#8209;dose toxicology studies which
were consistent with the pharmacological activity of apalutamide. In repeat&#8209;dose
toxicity studies in male rats and dogs, atrophy, aspermia/hypospermia,
degeneration and/or hyperplasia or hypertrophy in the reproductive system were
observed at doses corresponding to exposures approximately equal to the human
exposure based on AUC.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In a fertility study in male rats, a decrease in sperm
concentration and motility, copulation and fertility rates (upon pairing with
untreated females) along with reduced weights of the secondary sex glands and
epididymis were observed following 4&nbsp;weeks of dosing at doses corresponding
to exposures approximately equal to the human exposure based on AUC. Effects on
male rats were reversible after 8&nbsp;weeks from the last apalutamide
administration.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=EN-GB>Croscarmellose sodium</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypromellose acetate succinate</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=FR>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=FR>Microcrystalline cellulose (silicified)</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Film&#8209;coating</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Iron oxide black (E172)</span></p>

<p class=MsoNormal><span lang=EN-GB>Iron oxide yellow (E172)</span></p>

<p class=MsoNormal><span lang=EN-GB>Macrogol</span></p>

<p class=MsoNormal><span lang=EN-GB>Polyvinyl alcohol (partially hydrolysed)</span></p>

<p class=MsoNormal><span lang=EN-GB>Talc</span></p>

<p class=MsoNormal><span lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2 years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special temperature storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp; Nature and contents of
container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>White opaque high&#8209;density polyethylene
(HDPE) bottle with a polypropylene (PP) child&#8209;resistant closure. Each
bottle contains 120&nbsp;film&#8209;coated tablets and a total of 6 g of silica
gel desiccant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PVC&#8209;PCTFE
foil blister with an aluminum push&#8209;through foil</span><span lang=EN-GB> </span><span
lang=EN-GB>sealed inside a wallet pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each 28&#8209;day carton contains 112&nbsp;film
coated tablets in 4 cardboard wallet packs of 28&nbsp;film&#8209;coated tablets
each.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each 30&#8209;day carton contains 120&nbsp;film
coated tablets in 5 cardboard wallet packs of 24&nbsp;film&#8209;coated tablets
each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><a name="_Hlk496513351"><span
lang=EN-GB>Janssen&#8209;Cilag International NV</span></a></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Turnhoutseweg
30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/001</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/002</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 14 January
2019</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Detailed
information on this medicinal product </span><span lang=EN-GB>is available on
the website of the European Medicines Agency </span><span lang=EN-GB
style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:5.75pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>ANNEX II</span></b></p>

<p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EUCP-Heading-2><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=NL-BE style='color:black'>Janssen Cilag SpA</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=NL-BE style='color:black'>Via C. Janssen</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=NL-BE style='color:black'>Borgo San Michele</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>Latina 04100, Italy</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EUCP-Heading-2><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Medicinal product subject to restricted medical prescription
(see Annex I: Summary of Product</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EUCP-Heading-2><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:
Symbol;color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Periodic safety update
reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The requirements for submission of PSURs for this medicinal
product are set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates
published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The marketing authorisation holder (MAH) shall submit the
first PSUR for this product within 6&nbsp;months following authorisation.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EUCP-Heading-2><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:
Symbol;color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The marketing authorisation holder (MAH) shall perform the
required pharmacovigilance activities and interventions detailed in the agreed
RMP presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>At the request of the
European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=EUCP-Heading-1><span lang=EN-GB>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>CARTON 60&nbsp;mg (BOTTLE)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk499635221"><span lang=EN-GB>Erleada</span></a><span
lang=EN-GB> 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>120&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not swallow or discard the desiccant.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk501527652"><span lang=EN-GB>Store in original
package in order to protect from moisture</span></a><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><a name="_Hlk496513632"><span
lang=NL>Janssen&#8209;Cilag International NV</span></a></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>Erleada 60&nbsp;mg</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>BOTTLE LABEL 60&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk499626891"><span lang=EN-GB>Erleada 60&nbsp;mg film-coated
tablets</span></a></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk499626917"><span lang=EN-GB>Each tablet
contains 60&nbsp;mg apalutamide.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>120&nbsp;tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=ES>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=ES>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=ES>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE
OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>CARTON 60&nbsp;mg (28&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>112&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>CARTON 60&nbsp;mg (30&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>120&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>OUTER WALLET 60&nbsp;mg (28&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>28&nbsp;film&#8209;coated tablets per
wallet pack</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1) Press
and hold </span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=123 height=67
src="Erleada-II-009%20EN%20PI%20Clea_files/image006.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(2) Pull out</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=223 height=73
src="Erleada-II-009%20EN%20PI%20Clea_files/image007.gif"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>OUTER WALLET 60&nbsp;mg (30&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 60&nbsp;mg
apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>24&nbsp;film&#8209;coated tablets per wallet
pack</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk499627405"><span
lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1) Press
and hold </span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=123 height=67
src="Erleada-II-009%20EN%20PI%20Clea_files/image006.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(2) Pull out</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=223 height=73
src="Erleada-II-009%20EN%20PI%20Clea_files/image007.gif"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>Turnhoutseweg 30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/18/1342/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Erleada 60&nbsp;mg</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-AU style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>INNER WALLET 60&nbsp;mg (28&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Fold over to
close </span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=159 height=55
src="Erleada-II-009%20EN%20PI%20Clea_files/image008.jpg"></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Flip open</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=200 height=64
src="Erleada-II-009%20EN%20PI%20Clea_files/image009.jpg"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal><span lang=EN-GB>Sunday</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>INNER WALLET 60&nbsp;mg (30&nbsp;days)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Fold over to
close</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=159 height=55
src="Erleada-II-009%20EN%20PI%20Clea_files/image008.jpg"></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Flip open</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=200 height=64
src="Erleada-II-009%20EN%20PI%20Clea_files/image009.jpg"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Fill in your weekdays</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Start date:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Day</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><a name="_Hlk499705136"><b><span lang=EN-GB>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>BLISTER 60&nbsp;mg (12 count) (Blister sealed
in inner wallet)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg <span style='background:
silver'>film&#8209;coated tablets</span></span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:silver'>Janssen&#8209;Cilag International NV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>BLISTER 60&nbsp;mg (16 count) (Blister sealed
in inner wallet)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada 60&nbsp;mg <span style='background:
silver'>film&#8209;coated tablets</span></span></p>

<p class=MsoNormal><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:silver'>Janssen&#8209;Cilag International NV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=EUCP-Heading-1><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Erleada
60&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>apalutamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
src="Erleada-II-009%20EN%20PI%20Clea_files/image001.gif"></span><span
lang=EN-GB>This medicine is subject to additional monitoring. This will allow
quick identification of new safety information. You can help by reporting any
side effects you may get. See the end of section&nbsp;4 for how to report side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Erleada is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take Erleada</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take Erleada</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Erleada</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Erleada is and
what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada is a cancer medicine that contains the
active substance apalutamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>It is used </span>to
treat adult men with prostate cancer that:</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has metastasised to other parts of the body and
still responds to medical or surgical treatments that lower testosterone (also
called hormone-sensitive prostate cancer).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has not metastasised to other parts of the body
and no longer responds to medical or surgical treatment that lowers
testosterone (also called castration-resistant prostate cancer).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada works by blocking the activity of
hormones called androgens (such as testosterone). Androgens can cause the
cancer to grow. By blocking the effect of androgens, apalutamide stops prostate
cancer cells from growing and dividing.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to
know before you take Erleada</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take Erleada if</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you are allergic to apalutamide or any of the
other ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you are a woman who is pregnant or may become
pregnant (see the Pregnancy and contraception section below for more
information).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take this medicine if any of the
above apply to you. If you are not sure, talk to your doctor or pharmacist
before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk526335694"><b><span
lang=EN-GB>Warnings and precautions</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk526335490"><span
lang=EN-GB>Talk to your doctor or pharmacist before taking this medicine if:</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have ever had fits or seizures</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you are taking any medicines to prevent blood
clots (e.g. warfarin, acenocoumarol)<a name="_Hlk526335504"></a></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have any heart or blood vessel conditions,
including heart rhythm problems (arrhythmia).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Falls have been observed in patients taking
Erleada. Take extra care to reduce your risk of a fall. Broken bones have been observed
in patients taking Erleada.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Blockage of the arteries in the heart or in
part of the brain that can lead to death has happened in some people during
treatment with Erleada. Your healthcare provider will monitor you for signs and
symptoms of heart or brain problems during your treatment with Erleada. Call
your healthcare provider or go to the nearest emergency room right away if you
get chest pain or discomfort at rest or with activity, or shortness of breath,
or if you get muscle weakness/paralysis in any part of the body, or difficulty
in speaking during your treatment with Erleada.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any medicines, talk to
your doctor or pharmacist to see if they are associated with an increased risk
of seizure, bleeding or heart condition.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor or pharmacist before taking Erleada.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine is not for use in children
and adolescents under 18&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If a child or young person accidentally takes
Erleada:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>go to the hospital straight away</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>take this package leaflet with you to show to
the emergency doctor.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Erleada</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking, have recently taken,</span><span lang=EN-GB> </span><span lang=EN-GB>or
might take </span><span lang=EN-GB>any other medicines. This is because Erleada
can affect the way some other medicines work. Also, some other medicines can
affect the way Erleada works.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you are taking medicines that:</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower high fat levels in the blood (e.g.
gemfibrozil)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat bacterial infections (e.g. moxifloxacin,
clarithromycin)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat fungal infections (e.g. itraconazole,
ketoconazole)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat HIV infection (e.g. ritonavir, efavirenz,
darunavir)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat anxiety (e.g. midazolam, diazepam)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat epilepsy (e.g. phenytoin, valproic acid)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat gastroesophageal reflux disease
(conditions where there is too much acid in the stomach) (e.g. omeprazole)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>prevent blood clots (e.g. warfarin, clopidogrel,</span><span
lang=EN-GB> </span><span lang=EN-GB>dabigatran etexilate)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat hayfever and allergies (e.g. fexofenadine)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower cholesterol levels (e.g. &#8216;statins&#8217;
such as rosuvastatin, simvastatin)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat heart conditions or lower blood pressure
(e.g. </span>digoxin, felodipine<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat heart rhythm problems (e.g. quinidine,
disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat thyroid conditions (e.g. levothyroxine)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat gout (e.g. colchicine)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower blood glucose (e.g. repaglinide)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat cancer (e.g. lapatinib, methotrexate)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat opioid addiction or pain (e.g. methadone)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treat serious mental illnesses (e.g.
haloperidol)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You need to list the names of the medicines
you take and show the list to your doctor or pharmacist when you start a new
medicine. Mention to your doctor</span><span lang=EN-GB> </span><span
lang=EN-GB>that you are taking Erleada if the doctor wants to start you on any
new medicine.</span><span lang=EN-GB> </span><span lang=EN-GB>The dose of Erleada
or any other medicines that you are taking may need to be changed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and contraception information for men and women</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Information
for women</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Erleada must not be taken by women who are
pregnant, may become pregnant, or who are breast-feeding. Erleada may harm your
unborn baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Information
for men &#8211; follow this advice during treatment and for 3&nbsp;months after
stopping</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are having sex with a pregnant woman
&#8211; use a condom to protect the unborn baby.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are having sex with a woman who can
become pregnant &#8209; use a condom and another highly effective method of
contraception.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Use contraception during treatment and for 3&nbsp;months
after stopping. Talk to your doctor if you have any questions about
contraception.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Erleada may reduce male fertility.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine is not likely to affect you
being able to drive and use any tools or machines. The side effects for Erleada
include seizures. If you are at higher risk of seizures (see Section 2 Warnings
and precautions), talk to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Erleada
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than 1 mmol
sodium (23 mg) per 240 mg dose (4 tablets), that is to say essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; H</span><span
lang=EN-GB>ow to take Erleada</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always take </span><span lang=EN-GB>this
medicine</span><span lang=EN-GB> exactly as your doctor</span><span lang=EN-GB>
</span><span lang=EN-GB>has told you. Check with your doctor or pharmacist if
you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How much
to take</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The </span><span lang=EN-GB>recommended</span><span
lang=EN-GB> dose is 240&nbsp;mg (four 60 mg tablets) once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Taking Erleada</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take this medicine by mouth.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can take Erleada with food or between meals.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets whole.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your doctor may
also prescribe other medicines while you are taking Erleada.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more Erleada than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you take more than you should, stop
taking Erleada and contact your doctor. You may have an increased risk of side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take Erleada</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you forget to take Erleada, take your
usual dose as soon as you remember.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you forget to take Erleada for the whole day &#8209;
take your usual dose the following day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you forget to take Erleada for more than one
day &#8209; talk to your doctor straight away.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop taking Erleada</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not stop taking Erleada without checking
with your doctor first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Stop using Erleada and
seek medical attention immediately if you notice any of the following symptoms:</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>reddish non-elevated, target-like or circular patches on the
trunk, often with central blisters, skin peeling, ulcers of mouth, throat,
nose, genitals and eyes. These serious skin rashes can be preceded by fever and
flu-like symptoms (toxic epidermal necrolysis).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Serious side effects</b></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk526335546">Tell
your doctor straight away if you notice any of the following serious side
effects &#8211; your doctor may stop treatment:</a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fit or seizure &#8211; this is uncommon (may
affect up to 1 in 100&nbsp;people). Your healthcare provider will stop Erleada
if you have a seizure during treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk526335570"><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>falls or fractures (broken bones) &#8211; these are
very common (may affect more than 1 in 10&nbsp;people). Your healthcare
provider may monitor you more closely if you are at risk for fractures.</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart disease, stroke, or mini-stroke &#8211;
this is common (may affect up to 1 in 10&nbsp;people). Your healthcare provider
will monitor you for signs and symptoms of heart or brain problems during your
treatment. Call your healthcare provider or go to the nearest emergency room
right away if you get chest pain or discomfort at rest or with activity, or
shortness of breath, or if you get muscle weakness/paralysis in any part of the
body, or difficulty in speaking during your treatment with Erleada.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Tell your healthcare provider right away if you notice any
of the serious side effects above.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Side
effects include</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Very
common </span></b><span lang=EN-GB>(may affect more than 1 in 10&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling very tired</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flush</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>broken bones</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>falls</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight loss.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Common </span></b><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasms</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change in sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood test showing high level of cholesterol in
the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk526248640"><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood test showing high level of a type of fat
called &#8220;triglycerides&#8221; in the blood</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stroke or mini-stroke caused by low blood flow
to part of the brain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk518920145"><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>under&#8209;active thyroid which can make you
feel more tired and have difficulty getting started in the morning, and blood
tests may also show an under-active thyroid.</span></a></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon </span></b><span
lang=EN-GB>(may affect up to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>seizures/fits</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Not known
</span></b><span lang=EN-GB>(frequency cannot be estimated from the available
data):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal heart tracing on an ECG
(electrocardiogram)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>life-threatening rash with blisters and peeling
over much of the body (toxic epidermal necrolysis).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects, you can help provide more information
on the safety of this medicine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Erleada</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the container (blister foils, inner wallet, outer
wallet, bottle, and carton) after EXP. The expiry date refers to the last day
of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original package in order to
protect from moisture. This medicine does not require any special temperature storage
conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not </span><span lang=EN-GB>throw away
any medicines </span><span lang=EN-GB>via wastewater or household waste. Ask
your pharmacist how to </span><span lang=EN-GB>throw away </span><span
lang=EN-GB>medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What Erleada
contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is apalutamide. Each film&#8209;coated
tablet contains 60&nbsp;mg of apalutamide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients of the tablet core are colloidal
anhydrous silica, croscarmellose sodium, hypromellose acetate succinate,
magnesium stearate, microcrystalline cellulose, and silicified microcrystalline
cellulose. The film&#8209;coating contains iron oxide black (E172), iron oxide
yellow (E172), macrogol, polyvinyl alcohol (partially hydrolysed), talc, and
titanium dioxide (E171).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What Erleada
looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Erleada film-coated tablets are slightly
yellowish to greyish green, oblong&#8209;shaped, film&#8209;coated tablets (16.7&nbsp;mm
long x 8.7&nbsp;mm wide), with &#8220;AR 60&#8221; written on one side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablets may be supplied either in a
bottle or in a wallet pack. Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Bottle</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The tablets are supplied in a plastic
bottle with a child&#8209;resistant closure. Each bottle contains 120&nbsp;tablets
and a total of 6 g of desiccant. Each carton contains one bottle. Store in the
original package. Do not swallow or discard desiccant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>28&#8209;day
carton</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Each 28&#8209;day carton contains 112&nbsp;film&#8209;coated
tablets in 4&nbsp;cardboard wallet packs of 28&nbsp;film&#8209;coated tablets
each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>30&#8209;day
carton</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Each 30&#8209;day carton contains 120&nbsp;film&#8209;coated
tablets in 5&nbsp;cardboard wallet packs of 24&nbsp;film&#8209;coated tablets
each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Janssen&#8209;Cilag
International NV</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Turnhoutseweg
30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>B&#8209;2340
Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen Cilag SpA</span></p>

<p class=MsoNormal><span lang=NL>Via C. Janssen</span></p>

<p class=MsoNormal><span lang=NL>Borgo San Michele</span></p>

<p class=MsoNormal><span lang=NL>Latina 04100, Italy</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen&#8209;Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>Janssen&#8209;Cilag NV</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l/Tel</span><span lang=NL-BE>:
  +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen&#8209;Cilag s.r.o.</span></p>
  <p class=MsoNormal><a name="_GoBack"></a><span lang=FI>Tel.: +420 227 012 227</span></p>
  <p class=MsoNormal><b><span lang=FI>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=FI>Janssen&#8209;Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NO-BOK>Janssen&#8209;Cilag A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Janssen&#8209;Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen&#8209;Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=DE>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Eesti</span></b></p>
  <p class=MsoNormal><span lang=FI>UAB </span><span lang=FI>&quot;JOHNSON &amp;
  JOHNSON&quot;</span><span lang=FI style='layout-grid-mode:line'> Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tel: +372
  617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>ee@its.jnj.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal><span lang=NO-BOK>Janssen&#8209;Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag<span
  style='layout-grid-mode:line'>
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>T</span><span
  lang=EL style='layout-grid-mode:line'>&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>Janssen&#8209;Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Janssen&#8209;Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>Janssen&#8209;Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=PL>Tel.:+48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=PL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Janssen&#8209;Cilag</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l: 0 800 25 50 75 / +33 1 55 00
  40 03</span></p>
  <p class=MsoNormal><span lang=EN-GB>medisource@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Janssen&#8209;Cilag Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +351 214 368 600</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +385 1 6610 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson Rom&acirc;nia SRL</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +40 21 207 1800</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='layout-grid-mode:line'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL>c/o Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +421 232 408 400</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=IT>janssenita@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Janssen&#8209;Cilag Oy</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EL>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: </span><span lang=EL>+357
  22 207 700</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=DE>Janssen&#8209;Cilag AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tfn</span><span lang=EN-GB>: +46 8 626 50
  00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB </span><span lang=EN-GB>&quot;JOHNSON
  &amp; JOHNSON&quot;</span><span lang=EN-GB> fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>United Kingdom (Northern Ireland)</span></b></p>
  <p class=MsoNormal><span lang=SV>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last </span><span
lang=EN-GB>revised in </span></b><b><span lang=EN-GB>MM/YYYY</span></b><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: </span><span lang=EN-GB
style='color:blue'><a href="http://www.ema.europa.eu%3c/">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
